Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Buy

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Neutral

Analyst Rating

Buy

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Buy

A

()

No description provided.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

01/01/1970

Market Cap

N/A

Shares Outstanding

N/A

Weighted SO

N/A

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

Beta

N/A

Last Div

N/A

Range

N/A

Chg

N/A

Avg Vol

N/A

Mkt Cap

N/A

Exch

N/A

Country

N/A

Phone

N/A

DCF Diff

N/A

DCF

N/A

Div Yield

N/A

P/S

N/A

EV Multiple

N/A

P/FV

N/A

Div Yield %

N/A

P/E

N/A

PEG

N/A

Payout

N/A

Current Ratio

N/A

Quick Ratio

N/A

Cash Ratio

N/A

DSO

N/A

DIO

N/A

Op Cycle

N/A

DPO

N/A

CCC

N/A

Gross Margin

N/A

Op Margin

N/A

Pretax Margin

N/A

Net Margin

N/A

Eff Tax Rate

N/A

ROA

N/A

ROE

N/A

ROCE

N/A

NI/EBT

N/A

EBT/EBIT

N/A

EBIT/Rev

N/A

Debt Ratio

N/A

D/E

N/A

LT Debt/Cap

N/A

Total Debt/Cap

N/A

Int Coverage

N/A

CF/Debt

N/A

Equity Multi

N/A

Rec Turnover

N/A

Pay Turnover

N/A

Inv Turnover

N/A

FA Turnover

N/A

Asset Turnover

N/A

OCF/Share

N/A

FCF/Share

N/A

Cash/Share

N/A

OCF/Sales

N/A

FCF/OCF

N/A

CF Coverage

N/A

ST Coverage

N/A

CapEx Coverage

N/A

Div&CapEx Cov

N/A

P/BV

N/A

P/B

N/A

P/S

N/A

P/E

N/A

P/FCF

N/A

P/OCF

N/A

P/CF

N/A

PEG

N/A

P/S

N/A

EV Multiple

N/A

P/FV

N/A

DPS

N/A

Latest Headlines (EST)

Benzinga Apr 10, 21:02 FDA Grants Complete Approval To Bayer's Drug For Certain Type Cancer With Mutation GlobeNewswire Inc. Mar 27, 14:00 Biopesticides Market to Reach USD 25.82 Billion by 2032 | SNS Insider GlobeNewswire Inc. Mar 10, 00:30 Global Prostate Cancer Market to Reach USD 29.2 Billion by 2035, Driven by Aging Population and Awareness | Future Market Insights, Inc. GlobeNewswire Inc. Feb 08, 22:40 EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting GlobeNewswire Inc. Feb 08, 20:55 Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals Benzinga Dec 17, 18:05 Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease Study GlobeNewswire Inc. Dec 02, 23:30 Agrochemicals Market Poised for Significant Growth, Projected to Reach $282.2 Billion by 2028 GlobeNewswire Inc. Oct 18, 21:05 Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema GlobeNewswire Inc. Aug 22, 21:30 Targeted Therapeutics Market is Pioneering Growth Towards a USD 118.6 Billion Milestone by 2031, with a CAGR of 6.4% - Exclusive Report by Transparency Market Research, Inc. GlobeNewswire Inc. Aug 22, 00:30 Nutricosmetics Market Are Expected to Reach an Industry Valuation of USD 15,398.7 Million in the Year 2034 | Future Market Insights Inc. GlobeNewswire Inc. Jul 17, 05:32 Inside information: Phase III ARANOTE trial of darolutamide - GlobeNewswire

Revenue Product Segmentation